Exploring pathways leading to drug-resistant epilepsy for patients with cryptogenic new onset refractory status epilepticus - PubMed
5 days ago
- #biomarkers
- #NORSE epilepsy
- #neuroinflammation
- Study focuses on cryptogenic new onset refractory status epilepticus (cNORSE) and its pathways to drug-resistant epilepsy.
- Inflammatory and brain injury biomarkers were assessed for predictive value in cNORSE outcomes.
- Elevated innate cytokines and brain injury biomarkers during cNORSE correlated with worse functional outcomes.
- Serum neurofilament light chain (NfL) improved poor outcome prediction when added to cytokine models.
- Post-cNORSE epilepsy was associated with prolonged status epilepticus, MRI abnormalities, and intensive treatment needs.
- Most serum cytokines normalized in the chronic phase, but new adaptive immune disturbances appeared in 20% of patients.
- Persistently elevated NfL levels were more frequent in post-cNORSE epilepsy, suggesting ongoing axonal injury.
- Innate immune activation is acute in cNORSE but largely resolves, indicating it's not the driver of chronic epilepsy.
- Persistent NfL elevation suggests ongoing axonal injury, contributing to poor outcomes.
- Combining inflammatory and neuroaxonal injury biomarkers may improve risk stratification and long-term management.